Patents by Inventor Lindy Gillian Durrant

Lindy Gillian Durrant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
    Patent number: 10835618
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • Glycans as functional cancer targets and antibodies thereto
    Patent number: 10072073
    Abstract: A glycan having the structure gal?1-3GLcNac?1-3Gal?1-4(Fuc?1-3)GlcNAc (LecLex) which is attached to a lipid or protein backbone, and isolated binding members capable of binding thereto.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: September 11, 2018
    Assignee: The University of Nottingham
    Inventors: Lindy Gillian Durrant, Jiaxin Chua, Tina Rose Parsons
  • SIALYL-DI-LEWIS A AS EXPRESSED ON GLYCOPROTEINS BUT NOT GLYCOLIPIDS AS A FUNCTIONAL CANCER TARGET AND ANTIBODIES THERETO
    Publication number: 20180236095
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 23, 2018
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • CD55-INTERACTION PARTNERS AND THE USES THEREOF
    Publication number: 20170121418
    Abstract: The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventor: Lindy Gillian DURRANT
  • CD55-interaction partners and the uses thereof
    Patent number: 9580512
    Abstract: The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 28, 2017
    Assignee: Cancer Research Technology Limited
    Inventor: Lindy Gillian Durrant
  • GLYCANS AS FUNCTIONAL CANCER TARGETS AND ANTIBODIES THERETO
    Publication number: 20160264652
    Abstract: A glycan having the structure gal?1-3GLcNac?1-3Gal?1-4(Fuc?1-3)GlcNAc (LecLex) which is attached to a lipid or protein backbone, and isolated binding members capable of binding thereto.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 15, 2016
    Inventors: Lindy Gillian Durrant, Jiaxin Chua, Tina Rose Parsons